SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

MYX Mayne Pharma Group Limited

Healthcare · Medical Distribution · website · 363 employees
$2.85
52wk 2.04 – 6.50
Overall
49.4
Value
84.7
Growth
13.3
Health
64.6
Quality
22.7
Momentum
57.0
Dividend
—
Price
About Mayne Pharma Group Limited

Mayne Pharma Group Limited, a specialty pharmaceutical company, focuses on the commercialization of women's health and dermatology pharmaceuticals in Australia, New Zealand, the United States, Canada, Europe, Asia, and internationally. It operates through three segments: Women's Health, Dermatology, and International. The company provides oral drug delivery systems, as well as contract development and manufacturing services to third party customers. It also distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Price analytics

Returns

1 day 0.0%
1 week 1.4%
1 month -8.4%
3 months -1.0%
6 months 23.4%
1 year -49.5%
3 years -6.6%

Risk

Volatility (1y ann.) 67.2%
Beta vs ASX 200 1.16
Sharpe (1y) -0.71
VaR 95% (1-day) -5.0%
Max drawdown (1y) -66.2%
Off 1-year high -54.8%

Technicals

RSI(14) 34
vs 50DMA -6.0%
vs 200DMA 4.9%
Trend Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 84.7
Trailing P/E
100
Forward P/E
100
PEG ratio
19
EV / EBITDA
88
Price / Book
100
Price / Sales
100
Growth 13.3
Revenue growth (1y)
22
Revenue CAGR (3y)
5
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 64.6
Net debt / EBITDA
100
Interest coverage (EBIT/interest)
11
Current ratio
30
Debt / Equity
100
Quality (Profitability & Cash Flow) 22.7
Return on equity
41
Return on assets
0
Operating margin
0
Net margin
42
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 57.0
6-month return vs ASX 200
100
Price vs 200-day average
66
Price vs 50-day average
20
Position in 52-week range
18

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$233.39M
P/E (trailing)
7.31
P/E (forward)
-8.48
EPS (trailing)
0.39
Dividend yield
—
Payout ratio
0.0%
Beta
1.01
EV / EBITDA
5.88
Price / Book
0.57
ROE
8.2%
Operating margin
-2.9%
Net margin
6.4%
Total cash
$80.00M
Total debt
$43.20M
Current ratio
1.31
Debt / Equity
0.11
Free cash flow
$37.73M
Avg volume
227,568
Latest annual results (FY ending 30 Jun 2026)
  • Revenue$378.37M
  • Gross profit$242.76M
  • Operating income$78.18M
  • Net income$24.47M
  • Diluted EPS0.23
  • Free cash flow$10.55M
  • Net debt-$36.81M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4